Open Access Research Article

FROM VOLUNTARY CODE TO STATUTORY REGULATION: RETHINKING THE REGULATION OF PHARMACEUTICAL MARKETING IN INDIA

Author(s):
SARTHAK RAI RISHI VERMA
Journal IJLRA
ISSN 2582-6433
Access Open Access
Volume 3
Issue 7
Download PDF Open PDF Citation Search Scholar

Abstract

Pharmaceutical marketing occupies a distinctive position within commercial regulation because the consequences of promotional practices extend beyond ordinary consumer choice and can directly influence medical decision-making and public health. In India, the regulation of pharmaceutical marketing has primarily developed through the Uniform Code for Pharmaceutical Marketing Practices (“UCPMP”), which has historically operated as a voluntary framework. Although the UCPMP 2024 strengthened and expanded the regulatory standards applicable to pharmaceutical companies, its voluntary character raises fundamental questions concerning enforcement, accountability and the availability of effective remedies for violations. The Supreme Court’s decision in Federation of Medical Representatives Association of India v Union of India (“FMRAI”) brings these concerns into sharper focus and provides an opportunity to reconsider whether pharmaceutical marketing can adequately be regulated through voluntary industry standards. This paper examines the evolution of pharmaceutical marketing regulation in India and evaluates the structural limitations of the existing voluntary framework. It argues that the central weakness of the UCPMP is not merely the absence of statutory force, but the absence of an independent and effective enforcement architecture. Accordingly, simply granting statutory status to the existing Code would not, by itself, resolve the regulatory deficit. The paper proposes a broader statutory framework combining clearly defined prohibited practices, independent regulatory oversight, accessible complaint and investigation mechanisms, proportionate sanctions and mandatory transparency requirements. At the same time, it argues that regulation must distinguish between legitimate scientific and commercial communication and practices capable of improperly influencing medical decisions. The paper therefore advocates a model of regulated self-regulation in which industry expertise may contribute to standard-setting, while enforcement remains subject to independent statutory supervision. It concludes that an effective pharmaceutical marketing regime must move beyond voluntary ethical guidance towards a system of regulatory accountability capable of protecting the integrity of medical decision-making and, ultimately, patient interests.

Published Paper

PDF Preview
Download Open

Author Details

Authors: SARTHAK RAI & RISHI VERMARegistration ID: 1013350 | Published Paper ID: IJLRA13350 & IJLRA13351Year: Oct-2026 | Volume: 3 | Issue: 7Approved ISSN: 2582-6433 | Country: Delhi, IndiaPage No.: 1005- 1037

Article Information

FROM VOLUNTARY CODE TO STATUTORY REGULATION: RETHINKING THE REGULATION OF PHARMACEUTICAL MARKETING IN INDIA

Authors: SARTHAK RAI, RISHI VERMA

  • Journal IJLRA
  • ISSN 2582-6433
  • Volume 3
  • Issue 7
Citation Download Paper Full Details Search on Google Search on Google Scholar

About Journal

International Journal for Legal Research and Analysis

  • AbbreviationIJLRA
  • ISSN2582-6433
  • AccessOpen Access
  • LicenseCC 4.0

All research articles published in International Journal for Legal Research and Analysis are open access and available to read, download and share, subject to proper citation of the original work.

Creative Commons

Disclaimer: The opinions expressed in this publication are those of the authors and do not necessarily reflect the views of International Journal for Legal Research and Analysis.

Current Issue

Ethics and Policy

For Authors